Search

The Phages4Cure project is a German initiative (run by the Fraunhofer ITEM at Braunschweig in partnership with the DSMZ) to develop phage cocktails to treat P. aeruginosa in the lung. Fraunhofer ITEM has been manufacturing biologics to GMP

The Phages4Cure project is a German initiative (run by the Fraunhofer ITEM at Braunschweig in partnership with the DSMZ) to develop phage cocktails to treat P. aeruginosa in the lung. Fraunhofer ITEM has been manufacturing biologics to GMP

Locus Biosciences announced it has opened enrollment for a Phase 1b clinical trial evaluating a CRISPR Cas3-enhanced phage (crPhage™) product that will target E. coli causing urinary tract infections. This is the world's first controlled cl

NIAID will renew funding ($102.5 million over 7 years) for the Antibacterial Resistance Leadership Group (ARLG), and this time it includes funds for a phage therapy study! The ARLG is a global consortium of scientific experts that leads a c

NIAID will renew funding ($102.5 million over 7 years) for the Antibacterial Resistance Leadership Group (ARLG), and this time it includes funds for a phage therapy study! The ARLG is a global consortium of scientific experts that leads a c

The Turner lab at Yale has successfully treated 13 patients with phages so far. Now, the team has been awarded support from the Blavatnik Fund, which helps Yale scientists commercialize their discoveries. The support has made it possible fo

The Turner lab at Yale has successfully treated 13 patients with phages so far. Now, the team has been awarded support from the Blavatnik Fund, which helps Yale scientists commercialize their discoveries. The support has made it possible fo

What's the path forward when it comes to phage therapy? According to Shawna McCallin of the University Hospital of Geneva and Phages4All, clinical data is the priority, but it won't be enough. "The recent bankruptcy of Achaogen, a biotech

What's the path forward when it comes to phage therapy? According to Shawna McCallin of the University Hospital of Geneva and Phages4All, clinical data is the priority, but it won't be enough. "The recent bankruptcy of Achaogen, a biotech

Harald Brüssow, guest editor of the recently completed "Hurdles for Phage Therapy to Become a Reality" issue of Viruses, has written an editorial on the work (30 papers) published in the issue. His take-home lessons for optimizing phage the

Harald Brüssow, guest editor of the recently completed "Hurdles for Phage Therapy to Become a Reality" issue of Viruses, has written an editorial on the work (30 papers) published in the issue. His take-home lessons for optimizing phage the

Mian Li Ooi and colleagues at the University of Adelaide and Ampliphi Biosciences published a paper on their use of phage therapy in a phase I clinical trial to treat patients with chronic rhinosinusitis caused by Staphylococcus aureus. The

Mian Li Ooi and colleagues at the University of Adelaide and Ampliphi Biosciences published a paper on their use of phage therapy in a phase I clinical trial to treat patients with chronic rhinosinusitis caused by Staphylococcus aureus. The

This NPR article discusses Locus Biosciences' upcoming E. coli urinary tract infection phage therapy trial and interviews one of the trial volunteers—Alfonso Evans, a US Army veteran who was paralyzed by a spinal cord injury and thus suffer

An interesting reflection by Prof. Marc Bonten of UMC Utrecht on the current impasse in the Netherlands when it comes to the need for phage clinical trials, and on UMCU's recent discussions with national health authorities on the matter.

An interesting reflection by Prof. Marc Bonten of UMC Utrecht on the current impasse in the Netherlands when it comes to the need for phage clinical trials, and on UMCU's recent discussions with national health authorities on the matter.

This NPR article discusses Locus Biosciences' upcoming E. coli urinary tract infection phage therapy trial and interviews one of the trial volunteers—Alfonso Evans, a US Army veteran who was paralyzed by a spinal cord injury and thus suffer

A new preprint by Dr. Aleksandra Petrovic Fabijan and colleagues at the Westmead Institute for Medical Research in Sydney, Australia and AmpliPhi Biosciences provides much-awaited data from their IV phage therapy treatment of 13 patients wi

A new preprint by Dr. Aleksandra Petrovic Fabijan and colleagues at the Westmead Institute for Medical Research in Sydney, Australia and AmpliPhi Biosciences provides much-awaited data from their IV phage therapy treatment of 13 patients wi

Adaptive Phage Therapeutics has partnered with Yale University to manufacture and supply phages for use in Yale's upcoming clinical trials.